Subscribe

  • How Can We Help You?

    Global Problem Solving from Covington: Deal with Complex Problems Anywhere in the World

Covington Represents Merck in Spin Off of $9 Billion Organon Business

Press Release June 3, 2021

  • News and Insights
  • Covington Represents Merck in Spin Off of 9 Billion Organon Business

Covington Represents Merck in Spin Off of $9 Billion Organon Business

June 3, 2021

LONDON—Covington represented Merck & Co., Inc., working as global corporate entity structuring counsel with Merck's broader in-house and external counsel teams in the spin-off of its women’s health, legacy products and biosimilars businesses to newly-created Organon & Co., which has listed on NYSE.

Organon will be a global healthcare company formed through a spinoff from Merck to focus on improving the health of women throughout their lives. It will have a portfolio of more than 60 medicines and products that help address a spectrum of conditions women face.

The Covington corporate team provided legal entity structuring and separation support for the formation of the new Organon group of companies. Work was led by partners Louise Nash, Jane Pinho, Tom Repke, and Bruce Wilson and special counsel Brandon Thompson, with regional leadership from Ingrid Rechtin (North America), Sergio Urias (LATAM), Catharina Min (Asia Pacific), Henning Bloss (Western Europe), Phil Tamussino (Eastern Europe), and Rupert Harper (Middle East). 

Related Professionals

Share links:

Share links:

Related Practices

Related Industries

Related Offices

Related Regions

Related News & Insights